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OBJECTIVES The purpose of this study was to describe the incidence and spectrum of perioperative cardiac
and noncardiac morbidity and mortality after transmyocardial laser revascularization (TMR)
and to identify predictors of these adverse clinical events.
BACKGROUND Clinical studies have demonstrated the efficacy of TMR for relieving angina pectoris,
although no study to date has specifically addressed the associated perioperative morbidity and
mortality.
METHODS Between October 1995 and August 1997, 34 consecutive patients with end-stage coronary
artery disease (CAD) underwent isolated TMR. The majority of patients (94%) had class III
or IV angina pectoris, and two patients (6%) had unstable symptoms preoperatively. Patient
records were reviewed for fatal and nonfatal adverse cardiac and noncardiac events.
RESULTS Perioperative death occurred in two patients (5.9%) due to cardiogenic shock complicating
acute myocardial infarction. Perioperative cardiac morbidity occurred in 16 patients (47.1%);
noncardiac morbidity was seen in 12 patients (35.3%). Preoperative unstable angina was the
only variable predictive of perioperative death (p 5 0.005). Cardiac (p 5 0.005) and
noncardiac (p , 0.001) morbidity rates were significantly higher for the initial 15 patients
undergoing the procedure. Other predictors of perioperative complications included lack of
postoperative treatment with a furosemide infusion (p # 0.04) and preoperative unstable
angina (p 5 0.05).
CONCLUSIONS Perioperative mortality in patients undergoing isolated TMR is low. Transmyocardial laser
revascularization patients are at higher risk for adverse perioperative cardiac and noncardiac
events, likely reflecting the lack of immediate benefit from the procedure in the setting of
severe CAD. These patients merit vigilant surveillance for adverse events and aggressive
medical management in the perioperative period. (J Am Coll Cardiol 1999;33:1021–6) ©
1999 by the American College of Cardiology
Transmyocardial laser revascularization (TMR) is an
emerging technique for the treatment of end-stage coronary
artery disease (CAD) not amenable to either percutaneous
angioplasty or bypass surgery. Beginning with the initial
published results of Frazier et al. (1), multiple studies (2–5)
have demonstrated improvements in anginal class after the
procedure. Improved perfusion by positron emission tomog-
raphy (1,2) and single-photon emission computed tomog-
raphy (3,4), as well as a reduction in ischemic wall motion
abnormalities by dobutamine stress echocardiography (6)
have been reported as well. However, unlike traditional
surgical revascularization, in the majority of patients these
clinical improvements have not been observed until at least
3 months postoperatively (1,3,4), making these patients
susceptible to perioperative ischemic complications. Despite
this, no study to date has specifically addressed the incidence
of perioperative mortality as well as cardiac and noncardiac
morbidity in this high risk patient population. The purpose
of the present study was twofold: to characterize the
incidence and spectrum of perioperative cardiac and non-
cardiac morbidity and mortality after TMR and to identify
the predictors of these clinical events.
METHODS
Transmyocardial laser revascularization. Between Octo-
ber 1995 and August 1997, 34 patients at Duke University
Medical Center underwent isolated TMR for the treatment of
severe, diffuse CAD not amenable to either coronary artery
bypass grafting (CABG) or angioplasty. Transmyocardial laser
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revascularization was performed through a left anterolateral
thoracotomy without cardiopulmonary bypass using an 800-W
CO2 laser (The Heart Laser, PLC Medical Systems, Inc.,
Milford, Massachusetts). Transmural penetration of laser
pulses was confirmed by intraoperative transesophageal echo-
cardiography (TEE). The mean number of transmural laser
channels confirmed by TEE was 22 6 10 per patient, with a
range of 10 to 45. Transmyocardial laser revascularization was
performed in myocardial regions determined to be ischemic by
preoperative thallium scintigraphy. Preoperative ejection frac-
tion was determined in all patients by resting multiple gated
acquisition radionuclide ventriculography (MUGA). All pa-
tients had cardiac catheterization preoperatively within six
months of surgery to assess their native coronary anatomy and
bypass graft disease status and to exclude them as candidates
for conventional revascularization.
Postoperative medical management consisted of an aspi-
rin (325 mg) the evening of surgery, intravenous nitroglyc-
erin and beta-blockade, as well as immediate resumption of
all preoperative cardiac medications. In addition, after the
initial 11 patients, all patients received a prophylactic
furosemide infusion (5 mg/h intravenous titrated to clinical
response, hemodynamics and fluid balance). Patients oth-
erwise received routine postoperative care. Inotropic and
intraaortic balloon pump (IABP) support were initiated
when necessary for hemodynamic compromise.
Clinical outcomes. The medical records of all 34 patients
were reviewed for all fatal and nonfatal adverse perioperative
events. All patients were followed by a single cardiologist
(C.L.D.) during their entire hospitalization to ensure con-
sistent reporting of clinical events. Perioperative morbidity
and mortality were defined as any fatal and nonfatal adverse
events occurring during or after operation within 30 days if
the patient was discharged or within any interval if the
patient was not discharged (7). Specific cardiac events
included: angina pectoris, acute myocardial infarction, con-
gestive heart failure, pleural effusion requiring drainage,
cardiac arrhythmia requiring treatment and hemodynamic
instability or severe ischemia requiring IABP therapy. Non-
cardiac morbidity included: renal failure (defined as a
twofold rise in creatinine over baseline), cerebral vascular
accident, pneumonia, sepsis (defined by positive blood
cultures) and anemia requiring blood transfusion.
Statistical analysis. Data were entered into a Dell Latitude
LM personal computer (Dell Computer Corporation, Aus-
tin, Texas) and analyzed using STATISTICA for windows
version 5.1 (StatSoft, Inc., Tulsa, Oklahoma). All data are
presented as the mean 6 SD. One-way analysis of variance
(ANOVA) was used to analyze variables associated with
fatal as well as nonfatal cardiac and noncardiac events (8).
When overall significance was found within the ANOVA,
Tukey’s honest significant difference test was used to delin-
eate which comparisons were significantly different (8).
Statistical significance was considered a p value of ,0.05.
The study was approved by the institutional review board
of Duke University Medical Center. All subjects gave
informed consent before enrollment. All procedures fol-
lowed were in accordance with institutional guidelines.
RESULTS
Demographics. Patient demographics are presented in Ta-
ble 1. The study population consisted of 34 patients (13
female) with a mean age of 59.6 6 9.4 years (range 43 to
75). Thirty-two of the 34 patients had class III or IV angina
pectoris; two patients had unstable angina preoperatively
requiring intravenous nitrate and heparin therapy. Mean
preoperative left ventricular ejection fraction by resting
MUGA was 51 6 9% (range 35 to 71). The range of cardiac
medications taken preoperatively is presented in Table 2.
Follow-up results. Mean postoperative length of stay was
9.6 6 16.4 days; mean intensive care unit stay was 1.9 6 2.1
days. Mean duration of mechanical ventilation was 0.4 6 0.3
days. Swan–Ganz catheter use averaged 1.2 6 1.7 days. Nine
patients (27%) required postoperative inotropic support.
Perioperative mortality. Perioperative death occurred in 2
patients (5.9%). Both deaths resulted from complications of
perioperative myocardial infarction (MI). The first patient
died of progressive cardiogenic shock on postoperative day
8. Autopsy revealed recent (within one week) infarction of
Abbreviations and Acronyms
ANOVA 5 analysis of variance
CABG 5 coronary artery bypass grafting
CAD 5 coronary artery disease
IABP 5 intraaortic balloon pump
MI 5 myocardial infarction
MUGA 5 multiple gated acquisition radionuclide
ventriculography
TEE 5 transesophageal echocardiography
TMR 5 transmyocardial laser revascularization
Table 1. Patient Demographics
Patients 34 (13 female)
Mean age (yr) 59.6 6 9.4
Preoperative class III–IV angina 32 (94%)
Preoperative unstable angina 2 (6%)
Preoperative ejection fraction 51 6 9%
Diabetes mellitus 24 (71%)
Prior remote MI 26 (76%)
Prior CABG 31 (91%)
Prior redo-CABG 16 (47%)
Hypertension 32 (94%)
Recent smoking (,30 days preoperatively) 6 (18%)
Family history of CAD 21 (62%)
Hyperlipidemia 32 (94%)
CABG 5 coronary artery bypass grafting; CAD 5 coronary artery disease; MI 5
myocardial infarction.
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the anterolateral papillary muscle in addition to a right
ventricular infarction. The second patient suffered a periop-
erative MI and required IABP placement on the day of
surgery. His postoperative course was complicated by pro-
gressive hemodynamic deterioration due to ongoing isch-
emia. The patient died on postoperative day 51. No autopsy
was performed.
Perioperative cardiac morbidity. Perioperative cardiac
morbidity is outlined in Table 3. Overall, perioperative
cardiac events including angina pectoris, acute MI, conges-
tive heart failure, pleural effusion requiring drainage, cardiac
arrhythmia requiring treatment or need for IABP occurred
in 16 of the 34 patients (47.1%). Although all patients were
treated with intravenous nitroglycerin for at least the first
24 h postoperatively, 12 of 34 patients (35%) complained of
angina pectoris, and three of 34 (9%) sustained acute
myocardial infarction defined by new regional wall motion
abnormalities by two-dimensional echocardiography in con-
junction with ST changes consistent with myocardial injury.
Of the six patients with postoperative arrhythmia, there
were two episodes of atrial fibrillation, one episode of
junctional rhythm, two episodes of ventricular tachycardia
successfully treated with DC cardioversion and one terminal
episode of ventricular fibrillation. Of the two episodes of
ventricular tachycardia, one occurred intraoperatively and
was secondary to inadequate grounding of the electrocautery
device, and the second occurred on postoperative day 7 in a
patient suspected to have acute MI. Nearly one third of
patients had perioperative congestive heart failure (defined
by pulmonary congestion on chest X ray in the presence of
arterial hypoxemia) requiring an intensification of their
medical management. Both patients requiring postoperative
IABP sustained perioperative MI.
Perioperative noncardiac morbidity. Perioperative non-
cardiac morbidity is outlined in Table 4. Noncardiac com-
plications were seen in 12 patients (35.3%). Four patients
had a twofold or greater rise in their creatinine postopera-
tively, although no patient required dialysis. One patient
suffered a mild postoperative ischemic stroke with associated
facial droop and unilateral extremity weakness, which was
attributed to an embolic event in the setting of new onset
atrial fibrillation. The patient’s neurologic symptoms were
almost completely resolved at the time of her discharge on
postoperative day 14. Four patients developed postoperative
pneumonia requiring antibiotic therapy. Two patients had
sepsis with positive blood cultures postoperatively. The first
patient had methicillin-resistant staphylococcal sepsis com-
plicating postoperative pneumonia; the second patient had
enterococcal sepsis also from a pulmonary source.
Risk factor analysis. One-way ANOVA and Tukey’s hon-
est significant difference test (8) were used to analyze risk
factors for death and cardiac and noncardiac morbidity. Of
the variables analyzed (Table 5), only preoperative unstable
angina was predictive of perioperative death (Fig. 1). Early
experience with TMR (defined as the initial 15 patients
undergoing the procedure) (Fig. 2) and lack of immediate
postoperative therapy with a furosemide infusion (Fig. 3)
predicted perioperative cardiac and noncardiac morbidity
(Table 6). Preoperative unstable angina was also a risk factor
for adverse noncardiac events (Table 6).
DISCUSSION
Transmyocardial laser revascularization is an emerging tech-
nique for the treatment of end-stage coronary artery disease.
When the technique was first described for use in humans
(9), the mechanism of action was hypothesized to be direct
myocardial perfusion with left ventricular blood via the laser
channels. However, histologic studies in both humans
(10–12) and animal models (13) have failed to demonstrate
long-term channel patency. Subsequent basic scientific
studies (14–18) have cast doubt on this hypothesis as well,
with direct myocardial perfusion via TMR channels yet to
be demonstrated. Clinical studies of TMR (1,3,4) have
shown a delay in the clinical benefits of the procedure, with
improvements in anginal class often not evident until at least
3 months postoperatively. Consequently, unlike CABG,
Table 2. Preoperative Cardiac Medications
Medication
Number of Patients
Taking (%)
Aspirin 34 (100%)
Beta-blockers 31 (91%)
Nitrates 33 (97%)
Calcium channel blockers 30 (88%)
Diuretics 19 (56%)
ACE inhibitors 23 (68%)
Antilipid drugs 31 (91%)
ACE 5 angiotensin-converting enzyme.
Table 3. Perioperative Cardiac Morbidity
Angina pectoris 12 patients (35%)
Acute MI 3 patients (9%)
CHF 10 patients (29%)
Effusion 2 patients (6%)
Arrhythmia 6 patients (18%)
IABP 2 patients (6%)
CHF 5 congestive heart failure; IABP 5 intraaortic balloon pump; MI 5 myocardial
infarction.
Table 4. Perioperative Noncardiac Morbidity
Renal failure 4 patients (12%)
CVA 1 patient (3%)
Pneumonia 4 patients (12%)
Sepsis 2 patients (6%)
Transfusion 8 patients (24%)
CVA 5 cerebrovascular accident.
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which provides an immediate increase in myocardial perfu-
sion, patients undergoing TMR do not benefit immediately,
yet are subjected to all of the associated perioperative stress.
This situation places these patients at high risk for periop-
erative morbidity and mortality. Despite this, no study to
date has specifically addressed the incidence, spectrum and
risk factors for perioperative mortality as well as cardiac and
noncardiac morbidity after isolated TMR.
Perioperative mortality. This study demonstrates that
perioperative mortality after transmyocardial laser revascu-
larization is low. The perioperative mortality rate of 5.9%
seen in this study compares favorably with those of other
TMR patient series, which have reported mortality rates
ranging from 0% (5) to 20% (3), with the largest published
Table 5. One-Way Analysis of Variance of Potential Risk
Factors for Perioperative Death After Transmyocardial Laser
Revascularization
Variable
Patients Dying
(Mean Value)
Patients Surviving
(Mean Value)
Age (yr) 64.5 60.5
Female 0% 43.8%
Diabetes 50.0% 71.9%
EF ,40 0% 12.5%
Unstable angina 50.0%* 3.1%
Recent smoking 0% 18.8%
Prior MI 100% 75.0%
Prior CABG 100% 90.6%
Prior redo-CABG 50% 46.9%
# grafts patent 1.0 1.8
Pre-op beta-blocker 100% 90.6%
Pre-op calcium channel
blocker
100% 87.5%
Pre-op diuretic 0% 59.4%
Pre-op ACE inhibitor 50.0% 68.8%
Post-op furosemide
infusion
100% 65.6%
First 15 patients 50.0% 43.8%
*p 5 0.005.
ACE 5 angiotensin-converting enzyme; CABG 5 coronary artery bypass
grafting; EF 5 ejection fraction; MI 5 myocardial infarction; op 5 operative.
Figure 1. Graph of perioperative mortality rates in patients with
and without unstable angina preoperatively. The rate in patients
with unstable angina was 50% versus 3% in those without unstable
angina. Using one-way analysis of variance, unstable angina was
the only variable of those studied that was associated with an
increased risk of perioperative mortality (p 5 0.005). Solid bar 5
unstable angina; open bar 5 stable angina.
Figure 2. Graph of perioperative adverse cardiac and noncardiac
event rates in the first 15 (solid bars) versus the final 19 (open
bars) patients undergoing transmyocardial laser revascularization
at our institution. Patients among the initial 15 treated had
significantly higher rates of both cardiac (p 5 0.005) and noncar-
diac (p , 0.001) morbidity.
Figure 3. Graph of perioperative adverse cardiac and noncardiac
event rates in patients receiving (open bars) and not receiving
(solid bars) a furosemide infusion beginning in the immediate
postoperative period. Patients not receiving a furosemide infusion
had significantly higher rates of both cardiac (p 5 0.04) and
noncardiac (p 5 0.02) morbidity.
1024 Hughes et al. JACC Vol. 33, No. 4, 1999
Morbidity and Mortality After TMR March 15, 1999:1021–6
series to date quoting a perioperative mortality of 9% (4).
Both deaths in the present study were secondary to cardio-
genic shock after perioperative MI, consistent with prior
studies (2–4), which have found the majority of periopera-
tive deaths to be cardiac in nature.
The only variable predictive of perioperative death in this
study was the presence of unstable angina preoperatively.
This finding is similar to that of Lowe et al. (19), who
reported a total 6-month mortality of 6.5% in patients with
end-stage coronary disease initially randomized to TMR
versus a total mortality of 34.6% in patients with unstable
angina crossing over to TMR from medical management.
The authors of that multicenter prospective randomized
trial of TMR versus medical management recommended
TMR be offered to medically refractory patients with class
III or IV angina but not unstable angina. Unstable angina
represents an ischemic syndrome characterized by acute
plaque rupture and thrombus formation with a high risk of
subsequent myocardial infarction. Consequently, unstable
angina is considered a contraindication to TMR because of
the increased risk of MI and death.
Mortality for patients with a preoperative resting ejection
fraction less than 40% was not increased in this study.
Likewise, the mortality rate for patients receiving diuretics
or angiotensin-converting enzyme inhibitors preoperatively
was not significantly elevated either. This finding contrasts
with those of Frazier et al. (1), who found an increased risk
of adverse events in patients being treated for congestive
heart failure preoperatively. However, only four of the 34
patients in our series had an ejection fraction less than 40%,
and although there were no deaths in this group, the
number of patients is too small to draw any meaningful
conclusions. More recent studies of TMR have excluded
patients with an ejection fraction less than 30% (5).
Perioperative morbidity. This study is the first to fully
characterize the incidence and spectrum of perioperative
morbidity and mortality after TMR. The incidence of
cardiac (47.1%) and noncardiac (35.3%) morbidity observed
in this study is consistent with other series in the literature
(1–4,20), which have reported adverse perioperative events
in approximately one third of patients. Our incidence of
cardiac morbidity is slightly higher than other series, likely
because we included symptomatic ischemia, including an-
gina pectoris, as an adverse cardiac event. The incidence of
perioperative angina pectoris in the present study was 35%,
and accounted for the largest proportion of cardiac morbid-
ity.
One-way ANOVA revealed a significantly increased
incidence of adverse cardiac events among the first 15
patients undergoing TMR in our series. Cardiac morbidity
was seen in two thirds of this group versus approximately
one third of the final 19 patients. The major reason for the
decrease in cardiac morbidity in the final 19 patients was a
significant decrease in the incidence of congestive heart
failure. Of the 10 patients with perioperative congestive
failure requiring an intensification of medical therapy, 7
were among the first 15 patients to undergo TMR. These
early complications led to more aggressive medical therapy
in the immediate postoperative period, including the use of
higher doses of intravenous nitroglycerin, an intravenous
furosemide infusion and supplemental intravenous beta-
adrenergic blocking agents to minimize ischemia. Our
current postoperative medical regimen includes an aspirin
the evening of surgery, intravenous nitroglycerin and beta-
Table 6. One-Way Analysis of Variance of Potential Risk Factors for Perioperative Cardiac and Noncardiac Morbidity After
Transmyocardial Laser Revascularization
Variable
Patients With Cardiac
Morbidity (Mean Value)
Patients Without
Cardiac Morbidity
(Mean Value)
Patients With
Noncardiac Morbidity
(Mean Value)
Patients Without
Noncardiac Morbidity
(Mean Value)
Age (yr) 62.3 59.3 62.3 59.9
Female 31.3% 50.0% 41.7% 40.9%
Diabetes 81.3% 61.1% 66.7% 72.7%
EF ,40 6.3% 16.7% 0% 18.2%
Unstable angina 12.5% 0% 16.7%* 0%
Recent smoking 18.8% 16.7% 25.0% 13.6%
Prior MI 68.8% 83.3% 91.7% 68.2%
Prior CABG 87.5% 94.4% 91.7% 90.9%
Prior redo-CABG 37.5% 55.6% 41.7% 50.0%
# grafts patent 1.8 1.8 1.6 1.9
Pre-op beta-blocker 87.5% 94.4% 83.3% 95.5%
Pre-op calcium channel blocker 93.8% 83.3% 100% 81.8%
Pre-op diuretic 62.5% 50.0% 50.0% 59.1%
Pre-op ACE inhibitor 81.3% 55.6% 58.3% 72.7%
Post-op furosemide infusion 50.0%† 83.3% 41.7%‡ 81.8%
First 15 patients 68.8%§ 22.2% 91.7%\ 18.2%
*p 5 0.05. †p 5 0.04. ‡p 5 0.02. §p 5 0.005. \p , 0.001. Abbreviations as in Table 5.
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blockers for at least the first 24 h postoperatively and
immediate resumption of all preoperative cardiac medica-
tions. As noted, a prophylactic furosemide infusion is
initiated in the immediate postoperative period and contin-
ued for at least 24 h. The rationale for the furosemide
infusion is that we hypothesize that myocardial edema exists
postoperatively after laser injury of the myocardium, leading
to diastolic dysfunction and congestive heart failure. The
present study found that patients not receiving a prophylac-
tic furosemide infusion had an increased incidence of
cardiac events. Because all of the patients not receiving a
furosemide infusion were among the first 15 patients to
undergo TMR, this likely contributed substantially to the
higher incidence of cardiac morbidity in these patients.
The noncardiac morbidity rate was also significantly
lower among the final 19 (11%) versus the initial 15 patients
(67%), and among patients not receiving a prophylactic
furosemide infusion postoperatively. Three fourths of the
cases of both postoperative pneumonia and renal failure
occurred in the initial group of 15 patients undergoing
TMR. This increased incidence of both pneumonia and
renal failure is potentially related to the higher rate of
congestive heart failure seen in this group of patients as well.
Patients with unstable angina preoperatively also had a
higher incidence of noncardiac complications.
In summary, patients undergoing isolated TMR for
treatment of end-stage coronary artery disease are at in-
creased risk for perioperative cardiac and noncardiac mor-
bidity as compared with conventional bypass surgery. How-
ever, as evidenced by the change in adverse event rates
observed in our final 19 versus our initial 15 patients, an
acceptable morbidity rate can be achieved through aggres-
sive medical management in the early postoperative period.
This should include aspirin, intravenous nitroglycerin, in-
travenous beta-blockade and a furosemide infusion, as well
as early resumption of all preoperative cardiac medications.
This study also demonstrated that the mortality rate of
isolated TMR is low, although patients with unstable
angina and significantly impaired myocardial function
should not be considered candidates for the procedure.
Hopefully, by adopting the guidelines outlined, the risk of
perioperative morbidity and mortality with isolated TMR
can be minimized.
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